You are here: Industry Insights > vertex

News List

Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis drugs
July 24, 2019
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the submission of a New Drug Application (NDA) to the...
Vertex Submits NDA for Triple Combination of VX-445, Tezacaftor, Ivacaftor in Cystic Fibrosis americanpharmaceuticalreview
July 23, 2019
Vertex Pharmaceuticals announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen.
Vertex and Kymera to identify protein degradation therapeutics pharmaceutical-technology
May 22, 2019
Vertex Pharmaceuticals and Kymera Therapeutics have formed a strategic research and development (R&D) alliance to develop protein degradation medicines for various targets.
The price of access: Can the NHS afford Orkambi? pharmafile
May 09, 2019
The price of access: Can the NHS afford Orkambi?
Vertex Takes a Risk-based Approach to UAT contractpharma
April 16, 2019
Re-engineering processes with a modern EDC technology.
Vertex receives approval for CF drug in Australia biospectrumasia
March 20, 2019
Tezacaftor/ivacaftor in combination with ivacaftor was approved by the U.S. Food and Drug Administration (FDA) in February 2018, by Health Canada in June 2018 and by the European Commission in October 2018.
Vertex’ three-drug CF combo hits PhIII targets pharmatimes
March 08, 2019
Vertex’ three-drug cystic fibrosis regimen – combining the investigational next-generation corrector VX-445 with Kalydeco (ivacaftor) and tezacaftor – has achieved primary endpoints of two Phase III studies in patients the condition.
Vertex reports preliminary data for triple combination cystic fibrosis therapy pharmaceutical-technology
March 08, 2019
Boston-based pharmaceutical company Vertex has published promising interim analysis from two Phase III studies of a triple combination therapy of VX-445, tezacaftor and ivacaftor for cystic fibrosis.
Vertex's VX-445 triple combination regimen achieves main goals of two late-stage studies in CF firstwordpharma
March 07, 2019
Vertex Pharmaceuticals on Wednesday announced that a three-drug regimen combining the investigational next-generation corrector VX-445 with Kalydeco (ivacaftor) and tezacaftor met the primary endpoints of two Phase III studies in patients with cystic fibr
Vertex CEO, CCO head for U.K. hearing on Orkambi pricing standoff fiercepharma
March 05, 2019
Years into a standoff between Vertex Pharmaceuticals and NHS England over cystic fibrosis drug prices, the company's top brass is set to participate in a parliamentary hearing focused on pricing negotiations.

Previous page 1 2 3 4 5 6 7 Next page